GlassScriptPhysician profile
Thomas G Sheftel
NPI 1619060365
$4,042.47
in general payments reported to CMS, 2019-2025
27 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $716 · 2021: $612 · 2022: $367 · 2023: $343 · 2024: $526 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $538.55 | 2019-2025 | Arikayce |
| Viiv Healthcare Company | $530.36 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $512.95 | 2019-2025 | Delstrigo, Zerbaxa, Dificid |
| Gilead Sciences, INC. | $486.81 | 2019-2024 | |
| Abbvie INC. | $374.96 | 2020-2025 | Teflaro |
| Melinta Therapeutics, LLC | $311.08 | 2019-2025 | Orbactiv, Rezzayo, Vabomere |
| Janssen Biotech, INC. | $178.53 | 2019-2021 | |
| Theratechnologies INC. | $123.11 | 2019-2025 | Trogarzo, Egrifta |
| Shionogi INC | $111.72 | 2021-2022 | |
| Astellas Pharma US INC | $91.73 | 2022-2023 | Cresemba |
| Paratek Pharmaceuticals, INC. | $90.03 | 2022-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $86.16 | 2020-2024 | Hyqvia |
| Tetraphase Pharmaceuticals, INC. | $77.53 | 2019-2025 | |
| Angiodynamics, INC. | $69.81 | 2019 | |
| Pfizer INC. | $67.31 | 2020-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $62.93 | 2019-2021 | |
| Allergan, INC. | $56.20 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $51.76 | 2019-2020 | |
| Shire North American Group INC | $48.27 | 2019 | |
| Emd Serono, INC. | $34.21 | 2019-2020 | |
| Dynavax Technologies Corporation | $28.87 | 2019 | |
| X4 Pharmaceuticals, INC. | $26.99 | 2024 | Xolremdi |
| Grifols USA, LLC | $20.09 | 2021 | |
| La Jolla Pharmaceutical Company | $19.09 | 2023 | Xerava |
| Nabriva Therapeutics, Plc | $16.96 | 2020 | |
| Napo Pharmaceuticals INC | $14.74 | 2019 | |
| Mayne Pharma Commercial LLC | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sheftel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.